Contact Information
Business Development
Collaborations and partnerships are core components of Kancera’s business model. Kancera’s strategy is to develop and commercialize its candidate drugs by partnering with other leading biotech and pharmaceutical companies that are focusing on inflammation and oncology in the specialty care setting.
Please contact CEO Peter Selin for any business development enquiries: peter.selin@kancera.com
Investors
Kancera is publicly traded on the NASDAQ OMX First North Premier stock exchange. The company is developing a new class of drugs for treatment of inflammation and cancer.
The share is covered by Carlsquare, an independent equity research firm. Read Carlsquare’s most recent report here.
CEO Peter Selin is responsible for investor relations at Kancera. For any IR enquires please contact: peter.selin@kancera.com
Media
CEO Peter Selin is responsible for media and public relations at Kancera. For any enquires please contact: peter.selin@kancera.com
General enquiries
For any general enquires please contact: info@kancera.com